JP2017508144A5 - - Google Patents

Download PDF

Info

Publication number
JP2017508144A5
JP2017508144A5 JP2016551166A JP2016551166A JP2017508144A5 JP 2017508144 A5 JP2017508144 A5 JP 2017508144A5 JP 2016551166 A JP2016551166 A JP 2016551166A JP 2016551166 A JP2016551166 A JP 2016551166A JP 2017508144 A5 JP2017508144 A5 JP 2017508144A5
Authority
JP
Japan
Prior art keywords
sortilin
kit according
bipolar disorder
subject
subjects
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016551166A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017508144A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/052506 external-priority patent/WO2015121166A1/en
Publication of JP2017508144A publication Critical patent/JP2017508144A/ja
Publication of JP2017508144A5 publication Critical patent/JP2017508144A5/ja
Pending legal-status Critical Current

Links

JP2016551166A 2014-02-12 2015-02-06 感情／気分障害のバイオマーカーとしてのソルチリンの使用 Pending JP2017508144A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201400075 2014-02-12
DKPA201400075 2014-02-12
PCT/EP2015/052506 WO2015121166A1 (en) 2014-02-12 2015-02-06 Use of sortilin as biomarker for affective/mood disorders

Publications (2)

Publication Number Publication Date
JP2017508144A JP2017508144A (ja) 2017-03-23
JP2017508144A5 true JP2017508144A5 (enExample) 2018-03-22

Family

ID=52462923

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016551166A Pending JP2017508144A (ja) 2014-02-12 2015-02-06 感情／気分障害のバイオマーカーとしてのソルチリンの使用

Country Status (6)

Country Link
US (1) US20160349276A1 (enExample)
EP (1) EP3105594A1 (enExample)
JP (1) JP2017508144A (enExample)
CN (1) CN105980858A (enExample)
HK (1) HK1232289A1 (enExample)
WO (1) WO2015121166A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016164608A1 (en) 2015-04-07 2016-10-13 Alector Llc Methods of screening for sortilin binding antagonists
SI3280441T1 (sl) 2015-04-07 2022-01-31 Alector Llc Protitelesa anti-sortilin in metoda njihove uporabe
FR3057267A1 (fr) * 2016-10-11 2018-04-13 Centre National De La Recherche Scientifique - Cnrs - Procede de diagnostic/determination de l'efficacite de traitement de la depression
WO2019094757A1 (en) 2017-11-09 2019-05-16 The Trustees Of Columbia University In The City Of New York Pharmacological prophylactics against stress-induced affective disorders in females
US11622948B2 (en) 2017-11-09 2023-04-11 The Trustees Of Columbia University In The City Of New York Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders
LT3618928T (lt) 2018-07-13 2023-04-11 Alector Llc Anti-sortilino antikūnai ir jų panaudojimo būdai
CN111351945B (zh) * 2020-03-18 2021-04-23 东南大学 维生素d结合蛋白作为标志物在精神疾病抑郁症诊断中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3165537A1 (en) * 2008-12-19 2017-05-10 H. Lundbeck A/S Modulation of the vps 10-domain receptor family for the treatment of mental and behavioural disorders
GB0903417D0 (en) * 2009-02-27 2009-04-08 Cambridge Entpr Ltd Biomarkers
GB0922240D0 (en) * 2009-12-21 2010-02-03 Cambridge Entpr Ltd Biomarkers
GB201021502D0 (en) * 2010-12-20 2011-02-02 Cambridge Entpr Ltd Biomarkers

Similar Documents

Publication Publication Date Title
JP2017508144A5 (enExample)
Giaquinto et al. On the prognosis of outcome after stroke
Jha et al. Frailty in advanced heart failure: a systematic review
Tanizawa et al. The prognostic value of HRCT in myositis-associated interstitial lung disease
Sato et al. Anti-CADM-140/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease
Aw et al. Measurement of cardiac troponin I in serum with a new high-sensitivity assay in a large multi-ethnic Asian cohort and the impact of gender
CN105389465B (zh) 病历数据处理方法、装置以及系统
HK1258292A1 (zh) 使用il23途径生物标志物预测il23拮抗剂的临床应答
Goldberg et al. Predictive value of familiality, stressful life events and gender on the course of obsessive-compulsive disorder
Addissouky Detecting liver fibrosis by recent reliable biomarkers in viral hepatitis patients
WO2020055954A3 (en) Methods for detecting liver diseases
RU2019103403A (ru) Адреномедуллин для оценки застоя у индивидуума с острой сердечной недостаточностью
MX2018007589A (es) Ccl20 como indicador de respuesta clinica a antagonistas de il23.
Bellan et al. Association between red cell distribution width and response to methotrexate in rheumatoid arthritis
Ligon et al. Biomarkers in scleroderma: progressing from association to clinical utility
Lee et al. Distinct predictive factors influence on achievement of early molecular response by frontline imatinib in chronic phase chronic myeloid leukemia
JP2015528562A5 (enExample)
Petramala et al. Aldosterone-induced oxidative stress: a potential mechanism of aldosterone autonomy in primary aldosteronism
JP2011196840A (ja) 急性大動脈解離の検査方法
JP7497851B2 (ja) アルツハイマー病診断のためのアッセイ
Louie et al. The Course of Relapse Following Antipsychotic Discontinuation in Schizophrenia: A Test of the Antipsychotic Withdrawal Syndrome Hypothesis of Relapse
JP2015503106A5 (enExample)
Huang et al. Effects of continuous positive airway pressure on blood pressure in hypertensive patients with obstructive sleep apnoea
PL422387A1 (pl) Sposób oznaczania wrażliwości tkanek na insulinę, sposób identyfikacji insulinooporności i/lub określania predyspozycji do zaburzenia z nią związanego, zastosowanie wskaźnika insulinowrażliwości oraz zestawy diagnostyczne i ich zastosowania
Xue et al. Blood-brain barrier dysfunction predicts cognitive trajectory after ischemic stroke